The development of targeted therapy focuses on the inhibition of tumorigenesis and related signaling pathways in the tumor microenvironment.9 Angiogenesis is critical in the development and progression of malignant tumors and vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) signaling is one of the most predominant pathways for tumor angiogenesis.9 In the past 2 decades, therapies that target VEGF/VEGFR have been approved by the US Food and Drug Administration for patients with metastatic CRC. The gene discussed is VEGFA; the disease is neoplasm.